-
1.4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF 有权
标题翻译: 4-取代的苯甲酸化合物作为RORGAMAMT抑制剂及其用途公开(公告)号:US20150218096A1
公开(公告)日:2015-08-06
申请号:US14421048
申请日:2013-08-14
发明人: Kenneth J. Barr , Corey E. Bienstock , John K. Maclean , Hongjun Zhang , Richard T. Beresis , Dongshan Zhang , Neville J. Anthony , Blair T. Lapointe , Yuan Tian
IPC分类号: C07D209/26 , A61K31/437 , C07D231/56 , A61K31/416 , C07D401/06 , A61K31/404 , C07D403/06 , C07D405/06 , A61K31/5377 , C07D403/04 , C07D405/12 , C07D471/04 , A61K31/4439
CPC分类号: C07D209/26 , A61K31/404 , A61K31/416 , A61K31/437 , A61K31/4439 , A61K31/5377 , C07D231/56 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06 , C07D405/12 , C07D409/04 , C07D413/04 , C07D413/06 , C07D417/04 , C07D471/04 , Y02A50/409
摘要: The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
摘要翻译: 本发明涉及式I(式I)的化合物及其药学上可接受的盐或溶剂化物。 这些化合物可用于治疗RORGAMMT介导的疾病或病症。
-
2.3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as RORgammaT inhibitors and uses thereof 有权
标题翻译: 3-环己烯基和环己基取代的吲哚和吲唑化合物作为RORGAMAMT抑制剂及其用途公开(公告)号:US09487490B2
公开(公告)日:2016-11-08
申请号:US14421057
申请日:2013-08-14
发明人: Kenneth J. Barr , John K. Maclean , Hongjun Zhang , Richard T. Beresis , Dongshan Zhang , Brian M. Andresen , Neville J. Anthony , Blair T. Lapointe , Nunzio Sciammetta
IPC分类号: C07D471/04 , A61K31/4745 , C07D231/56 , A61K31/404 , A61K31/416 , A61K31/437 , A61K31/454 , A61K31/496 , A61K31/5377 , C07D209/26 , C07D401/06 , C07D403/06 , C07D405/12 , C07D413/06
CPC分类号: C07D231/56 , A61K31/404 , A61K31/416 , A61K31/437 , A61K31/454 , A61K31/496 , A61K31/5377 , C07D209/26 , C07D401/06 , C07D403/06 , C07D405/12 , C07D413/06 , C07D471/04 , Y02A50/409
摘要: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
-
公开(公告)号:US09745265B2
公开(公告)日:2017-08-29
申请号:US14421048
申请日:2013-08-14
发明人: Kenneth J. Barr , Corey E. Bienstock , John K. Maclean , Hongjun Zhang , Richard T. Beresis , Dongshan Zhang , Neville J. Anthony , Blair T. Lapointe , Yuan Tian
IPC分类号: C07D209/26 , C07D231/56 , C07D471/04 , C07D401/04 , C07D403/04 , C07D409/04 , C07D413/04 , C07D417/04 , C07D401/06 , C07D403/06 , C07D405/06 , C07D413/06 , A61K31/404 , A61K31/416 , A61K31/437 , A61K31/4439 , A61K31/5377 , C07D405/12
CPC分类号: C07D209/26 , A61K31/404 , A61K31/416 , A61K31/437 , A61K31/4439 , A61K31/5377 , C07D231/56 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06 , C07D405/12 , C07D409/04 , C07D413/04 , C07D413/06 , C07D417/04 , C07D471/04 , Y02A50/409
摘要: The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
-
4.3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF 有权
标题翻译: 3-氨基胆碱化合物作为RORGAMAMT抑制剂及其用途公开(公告)号:US20150218169A1
公开(公告)日:2015-08-06
申请号:US14421062
申请日:2013-08-14
发明人: Kenneth J. Barr , John K. Maclean , Hongjun Zhang , Richard T. Beresis , Neville J. Anthony , Matthew Daniels , Blair T. Lapointe , Nunzio Sciammetta
IPC分类号: C07D487/04 , C07D403/04 , A61K31/4155 , C07D401/04 , A61K31/454 , A61K31/46 , A61K31/415 , C07D401/14 , A61K31/4545 , A61K31/444 , A61K31/4439 , C07D451/02 , A61K31/437 , C07D231/56
CPC分类号: C07D487/04 , A61K31/415 , A61K31/4155 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/46 , A61P5/14 , A61P11/06 , A61P17/06 , A61P21/00 , A61P25/00 , A61P29/00 , A61P33/02 , A61P43/00 , C07D213/56 , C07D231/56 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D451/02 , C07D471/04 , C07D519/00 , Y02A50/409
摘要: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
摘要翻译: 本发明涉及式I化合物及其药学上可接受的盐或溶剂化物。 这些化合物可用于治疗RORGAMMT介导的疾病或病症。
-
公开(公告)号:US10196354B2
公开(公告)日:2019-02-05
申请号:US15647437
申请日:2017-07-12
发明人: Kenneth J. Barr , Corey E. Bienstock , John K. Maclean , Hongjun Zhang , Richard T. Beresis , Dongshan Zhang , Neville J. Anthony , Blair T. Lapointe , Yuan Tian
IPC分类号: C07D209/26 , C07D231/56 , C07D471/04 , C07D401/04 , C07D403/04 , C07D409/04 , C07D413/04 , C07D417/04 , C07D401/06 , C07D403/06 , C07D405/06 , C07D413/06 , A61K31/404 , A61K31/416 , A61K31/437 , A61K31/4439 , A61K31/5377 , C07D405/12
摘要: The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
-
6.3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF 有权
标题翻译: 3-环己基和环己基取代的吲哚和吲哚酮化合物作为RORGAMAMT抑制剂及其用途公开(公告)号:US20150191434A1
公开(公告)日:2015-07-09
申请号:US14421057
申请日:2013-08-14
发明人: Kenneth J. Barr , John K. Maclean , Hongjun Zhang , Richard T. Beresis , Dongshan Zhang , Brian M. Andresen , Neville J. Anthony , Blair T. Lapointe , Nunzio Sciammetta
IPC分类号: C07D231/56 , C07D471/04 , A61K31/437 , C07D403/06 , C07D413/06 , A61K31/404 , A61K31/496 , C07D405/12 , C07D401/06 , A61K31/454 , C07D209/26 , A61K31/416 , A61K31/5377
CPC分类号: C07D231/56 , A61K31/404 , A61K31/416 , A61K31/437 , A61K31/454 , A61K31/496 , A61K31/5377 , C07D209/26 , C07D401/06 , C07D403/06 , C07D405/12 , C07D413/06 , C07D471/04 , Y02A50/409
摘要: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
摘要翻译: 本发明涉及式I化合物及其药学上可接受的盐或溶剂化物。 这些化合物可用于治疗RORGAMMT介导的疾病或病症。
-
7.
公开(公告)号:US20180022701A1
公开(公告)日:2018-01-25
申请号:US15647437
申请日:2017-07-12
发明人: Kenneth J. Barr , Corey E. Bienstock , John K. Maclean , Hongjun Zhang , Richard T. Beresis , Dongshan Zhang , Neville J. Anthony , Blair T. Lapointe , Yuan Tian
IPC分类号: C07D209/26 , C07D471/04 , C07D401/06 , C07D403/06 , C07D405/06 , C07D413/06 , C07D401/04 , C07D403/04 , C07D409/04 , C07D413/04 , C07D417/04 , A61K31/404 , A61K31/5377 , A61K31/4439 , A61K31/437 , A61K31/416 , C07D405/12 , C07D231/56
CPC分类号: C07D209/26 , A61K31/404 , A61K31/416 , A61K31/437 , A61K31/4439 , A61K31/5377 , C07D231/56 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D405/06 , C07D405/12 , C07D409/04 , C07D413/04 , C07D413/06 , C07D417/04 , C07D471/04 , Y02A50/409
摘要: The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
-
公开(公告)号:US09663522B2
公开(公告)日:2017-05-30
申请号:US14421062
申请日:2013-08-14
发明人: Kenneth J. Barr , John K. Maclean , Hongjun Zhang , Richard T. Beresis , Neville J. Anthony , Matthew Daniels , Blair T. Lapointe , Nunzio Sciammetta
IPC分类号: C07D487/04 , C07D401/12 , C07D403/06 , C07D471/04 , C07D519/00 , C07D213/56 , C07D401/04 , C07D403/04 , A61K31/415 , A61K31/4155 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/46 , C07D231/56 , C07D401/14 , C07D451/02
CPC分类号: C07D487/04 , A61K31/415 , A61K31/4155 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4545 , A61K31/46 , A61P5/14 , A61P11/06 , A61P17/06 , A61P21/00 , A61P25/00 , A61P29/00 , A61P33/02 , A61P43/00 , C07D213/56 , C07D231/56 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D451/02 , C07D471/04 , C07D519/00 , Y02A50/409
摘要: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
-
9.N-alkylated indole and indazole compounds as RORgammaT inhibitors and uses thereof 有权
标题翻译: N-烷基化的吲哚和吲唑化合物作为RORGAMAMT抑制剂及其用途公开(公告)号:US09556168B2
公开(公告)日:2017-01-31
申请号:US14421052
申请日:2013-08-14
发明人: Kenneth J. Barr , Corey E. Bienstock , John K. Maclean , Hongjun Zhang , Richard T. Beresis , Neville J. Anthony , Blair T. Lapointe , Nunzio Sciammetta
IPC分类号: A61K31/00 , C07D471/04 , C07D231/56 , A61K31/416 , A61K31/437 , C07D403/06
CPC分类号: C07D471/04 , A61K31/416 , A61K31/437 , C07D231/56 , C07D403/06 , Y02A50/409
摘要: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
摘要翻译: 本发明涉及式I化合物及其药学上可接受的盐或溶剂化物。 这些化合物可用于治疗RORGAMMT介导的疾病或病症。
-
-
-
-
-
-
-
-